Loading market dashboard
Trevi Therapeutics, Inc.
TRVIHealthcareNASDAQUS
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
This clinical-stage biotech targets chronic pruritus and cough with its lead therapy for neurologically mediated diseases.
Trevi Therapeutics, Inc. (TRVI) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Trevi Therapeutics NASDAQ: TRVI outlined plans to advance Haduvio, its extended-release formulation of nalbuphine, across multiple chronic cough indications, with management emphasizing upcoming clinical trial starts, a specialty commercial strategy and an extended cash runway following a recent financing.
Trevi Therapeutics, Inc. (TRVI) Q1 2026 Earnings Call Transcript
Completed follow-on common stock offering with net proceeds of ~$162 million, extending expected cash runway into 2030 through potential FDA approval of Haduvio in IPF-related chronic cough and continued pipeline advancement Clinical development plans remain on track across all chronic cough indications Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn.
Primary and subgroup analysis from the Phase 2b CORAL trial of nalbuphine ER for the treatment of patients with IPF-related chronic cough accepted for oral presentation, including key subgroup analyses by baseline cough count and background anti-fibrotic use An exploratory post-hoc analysis of the effects of nalbuphine ER and placebo on cough bouts from the Phase 2b CORAL trial in patients with IPF-related chronic cough and the Phase 2a RIVER trial in patients with refractory chronic cough Drug–drug interaction data from a Phase 1 study evaluating pharmacokinetics and safety following co-administration of nalbuphine ER with pirfenidone or nintedanib NEW HAVEN, Conn., April 30, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy oral nalbuphine ER for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that it will deliver an oral presentation and present multiple abstracts at the American Thoracic Society (ATS) 2026 International Conference, taking place from May 15 – 20, 2026, in Orlando, Florida.
NEW HAVEN, Conn., April 28, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, May 5, 2026, at 4:30 p.m.
NEW HAVEN, Conn., April 23, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will participate in several upcoming events in May.
NEW HAVEN, Conn., April 20, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the closing of its previously announced underwritten public offering of 13,340,000 shares of its common stock at a public offering price of $13.00 per share, which includes 1,740,000 additional shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the public offering at the public offering price, less underwriting discounts and commissions. The total proceeds of the public offering were approximately $173 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. All of the shares in the offering were sold by Trevi.
Trevi Therapeutics, Inc. (NASDAQ: TRVI) shares are trading higher after the company announced the pricing of its $150 million offering of 11.6 million shares at $13 per share.
NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced the pricing of its previously announced underwritten public offering of 11,600,000 shares of its common stock at a public offering price of $13.00 per share, for total proceeds of approximately $150 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. All of the shares in the offering are being sold by Trevi. In addition, Trevi has granted the underwriters a 30-day option to purchase up to 1,740,000 additional shares of its common stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about April 20, 2026, subject to satisfaction of customary closing conditions.
NEW HAVEN, Conn., April 16, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. All of the shares in the offering are being offered by Trevi. In addition, Trevi expects to grant the underwriters a 30-day option to purchase up to an additional $22,500,000 of the shares of its common stock sold in the public offering at the public offering price, less underwriting discounts and commissions.
SG Americas Securities LLC raised its stake in Trevi Therapeutics, Inc. (NASDAQ: TRVI) by 93.0% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 124,562 shares of the company's stock after acquiring an additional 60,017 shares during the quarter. SG Americas
NEW HAVEN, Conn., April 01, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will be participating in the following events.
Trevi Therapeutics, Inc. (NASDAQ: TRVI - Get Free Report) has earned an average recommendation of "Buy" from the twelve ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and two have assigned a strong buy rating to the company.
Trevi Therapeutics (NASDAQ: TRVI - Get Free Report) and DNAPrint Genomics (OTCMKTS:DNAG - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends. Insider and Institutional Ownership 95.8% of Trevi Therapeutics
Trevi Therapeutics (NASDAQ: TRVI) used its fourth-quarter and year-end 2025 earnings call to outline next steps following what management described as a pivotal year driven by positive clinical data in two chronic cough programs. President and CEO Jennifer Good said 2025 marked a "major inflection point" for the company after favorable readouts from the CORAL trial
Trevi Therapeutics, Inc. (TRVI) Q4 2025 Earnings Call Transcript
Following the End-of-Phase 2 meeting with the FDA, the Company gained alignment on its Phase 3 program for the treatment of patients with idiopathic pulmonary fibrosis-related chronic cough
Trevi Therapeutics (NASDAQ: TRVI - Get Free Report) and Atea Pharmaceuticals (NASDAQ: AVIR - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, profitability, risk, institutional ownership and analyst recommendations. Analyst Ratings This is a breakdown of
NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, March 17, 2026, at 4:30 p.m.
TRVI, MTA and VET have posted strong one-year gains and now meet momentum and price-range screens that signal potential breakout opportunities in March.
T he Company will conduct two Phase 3 clinical trials of nalbuphine ER for the treatment of patients with IPF-related chronic cough
